In 2020, OpenText surveyed 125 pharmaceutical executives to determine how familiar each respondent is with AI technologies within their industry. The survey results revealed that an interest in AI increased to 85% in 2020, up from 47% in 2018, when a previous similar survey was conducted. Approximately 75% of respondents indicated they intend to or plan on using data scientists' analytics centers of excellence. Unlike with previous OpenText surveys, respondents indicated that issues with regulation and promotional content shy rocked to the top of the least organized areas, as opposed to document management and processing of regulatory submissions, which were well-defined areas. The incorporation of AI into the pharma industry provides a number of tangible advantages. Further findings from the recent OpenText survey revealed, the percentage of companies looking at next-generation technologies dropped from 23% in 2018 to 19% in 2020.